• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Grove Inc.

    11/30/22 4:05:30 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRVI alert in real time by email
    POS AM 1 upxi_posam.htm POS AM upxi_posam.htm

    As filed with the Securities and Exchange Commission on November 30, 2022

     Registration No. 333-267355

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     ________________________

     

    Post-Effective Amendment No. 1

    to

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ________________________

     

    Upexi, Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    5900

     

    83-3378978

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial Classification

    Code Number)

     

    (I.R.S. Employer

    Identification Number)

     

    17129 US Hwy 19 N.

    Clearwater, FL 33760

    (701) 353-5425

    (Address, including zip code, and telephone number, including area code, of principal executive offices)

    ________________________

     

    Andrew J. Norstrud

    Chief Financial Officer

    Upexi, Inc.

    17129 US Hwy 19 N.

    Clearwater, FL 33760

    (701) 353-5425

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    ________________________

     

    Copies to:

     

    Clint J. Gage, Esq.

    Jua T. Tawah, Esq.

    Dickinson Wright PLLC

    350 East Las Olas Blvd, Suite 1750

    Ft. Lauderdale FL 33301

    (954) 991-5420

     

    Approximate date of commencement of proposed sale to the public:  Not Applicable

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     ________________________

     

     

     

      

    EXPLANATORY NOTE –

    DEREGISTRATION OF SECURITIES

     

    This Post-Effective Amendment relates to the Registration Statement on Form S-3 (Commission File No. 333-267355), originally filed by Upexi, Inc., a Nevada corporation (“Upexi”), with the Securities and Exchange Commission (the “SEC”) on September 9, 2022 (as amended, the “Registration Statement”), registering 1,118,574 shares of Upexi’s common stock for resale, from time to time, by the selling shareholder named in the Registration Statement. The Registration Statement was declared effective by the SEC on September 20, 2022.

     

    Upexi has no further obligation to maintain effectiveness of the Registration Statement. In accordance with an undertaking made by Upexi in the Registration Statement to remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, this Post-Effective Amendment No. 1 is being filed to terminate the effectiveness of the Registration Statement and to remove from registration all securities registered but not sold under the Registration Statement. As a result of this deregistration, no securities remain registered for resale pursuant to the Registration Statement.

     

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, Upexi, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Clearwater, State of Florida, on November 30, 2022.

     

     

    Upexi, Inc.

     

     

     

     

     

     

    By:

    /s/ Allan Marshall

     

     

     

    Allan Marshall

     

     

     

    Chief Executive Officer and Chairman

    (Principal Executive Officer)

     

     

     

    3

     

    Get the next $GRVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRVI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRVI
    SEC Filings

    View All

    Grove Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/15/22 4:05:24 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Grove Inc.

    EFFECT - UPEXI, INC. (0001775194) (Filer)

    12/5/22 12:15:12 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grove Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/2/22 9:15:45 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Marshall Allan bought $63,909 worth of shares (17,303 units at $3.69), increasing direct ownership by 0.68% to 2,575,081 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    1/11/23 4:56:21 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $49,320 worth of shares (12,000 units at $4.11), increasing direct ownership by 0.47% to 2,557,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/13/22 5:48:52 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $73,161 worth of shares (18,475 units at $3.96), increasing direct ownership by 0.73% to 2,545,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/5/22 3:24:06 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Grove, Inc. Announces Name and Symbol Change to Upexi, Inc. "UPXI"

    HENDERSON, Nev., Aug. 17, 2022 /PRNewswire/ -- Grove Inc. (NASDAQ:GRVI), a market leader in Amazon and eCommerce brand ownership and aggregation, announces that today, August 17, 2022, its trading name on the Nasdaq officially changed from "Grove Inc." to "Upexi, Inc." and its ticker symbol changed from "GRVI" to "UPXI". This accompanies previous press releases notifying investors of this change. CEO Allan Marshall stated, "Last month, we announced our growth strategy in a letter to shareholders that focused on our acquisition plan to bring more, profitable eCommerce brands in various industries under our umbrella. Moving to a new name and stock ticker is a reflection of the progress we have

    8/17/22 4:05:00 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sidoti's August Micro-Cap Virtual Conference

    Presentation Times and Weblinks Released for Over 50 Presenting CompaniesWednesday and Thursday, August 17-18, 2022NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.Presentation AgendaWednesday, August 17th, 2022 (Day 1)*All Times EDT8:30-9:00Mativ Holdings, Inc. (MATV)Brenmiller Energy, Ltd. (BNRG)Sify Technologies Ltd (SIFY)9:15-9:45MISTRAS Group (MG)Bassett Furniture (BSET)Silvercrest Asset Management Group (SAMG)10:00-10:30Anebulo Pharmaceuticals (ANEB)*****

    8/16/22 3:00:00 PM ET
    $AIRI
    $ANEB
    $APRN
    Military/Government/Technical
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Update: Grove, Inc. to Present at Sidoti August Microcap Conference

    HENDERSON, NV , Aug. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove Inc. (GRVI) announced today that Allan Marshall, Chief Executive Officer, is scheduled to present virtually at the Sidoti & Company, August Virtual Microcap Conference on Wednesday, August 17, 2022 at 3:15 pm ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_FqCzxA3xTbOsMXr-Ml5X7Q Grove will also host virtual one-on-ones with investors throughout the conference.  To register for the presentation of a one-on-one meeting, visit https://www.sidoti.com/events/august-micro-cap-virtual-conference. Registration is free and you are not required to be a Sidoti & Company client. 

    8/10/22 10:56:39 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:08:22 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:48 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:14 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Financials

    Live finance-specific insights

    View All

    Grove, Inc. Announces Fiscal Year 2021 Audited Financial Results

    Revenues Reach $24.1 Million, a 250% Increase Over 2020 Net Earnings of $2.9 Million or $.25 Per Share HENDERSON, NV, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced audited financial results for its fiscal year ended June 30, 2021 which surpassed preliminary results issued on June 28, 2021.   Investors are encouraged to read the Company's annual report on Form 10-K which was filed with the Securities and Exchange Commission (the "SEC"), contains additional information, and is posted at https://groveinc.io/ Financial Highlights $2

    9/29/21 8:00:00 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care